Synergism from sequenced combinations of curcumin and epigallocatechin-3- gallate with cisplatin in the killing of human ovarian cancer cells

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1131-1140

  Yunos, Nurhanan M ^a,b   Beale, Philip ^c   Yu, Jun Q ^a   Huq, Fazlul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FOREST RESEARCH INSTITUTE MALAYSIA   (Malaysia)

^c Department of Geriatric Medicine   (Australia)

Author keywords

Cisplatin; Curcumin; Drug combination; EGCG; Ovarian cancer; Synergism

Indexed keywords

CISPLATIN; CURCUMIN; DNA; EPIGALLOCATECHIN GALLATE;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA BINDING; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OVARY CANCER; PHYTOCHEMISTRY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CATECHIN; CISPLATIN; CURCUMIN; DNA ADDUCTS; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 79956088980     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gallion HH, Pieretti M, DePriest PD and van Nagell JR Jr.: The molecular basis of ovarian cancer. Cancer 76(10 Suppl): 1992-1997, 1995.
2. Schuijer M and Berns EMJJ: TP53 and ovarian cancer. Hum Mut 21(3): 285-291, 2003. (Pubitemid 36292970)
3. Crul M, van Waardenburg RCAM, Beijnen JH and Schellens JHM: DNA-based drug interactions of cisplatin. Cancer Treatment Rev 28(6): 291-303, 2002. (Pubitemid 36054538)
4. Boulikas T and Vougiouka M: Cisplatin and platinum drugs at the molecular level. (Review). Oncol Reports 10(6): 1663-1682, 2003.
5. Alison M and Sarraf C: Understanding Cancer: From Basic Science to Clinical Practice. London, Cambridge University Press, 1997.
6. Rowinsky EK: Incorporating assessments of sequence-dependence in developmental studies of combination chemotherapy regimens containing new agents and platinum compounds. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Pinedo HM and Schornagel JH (eds.). New York, Plenum Press, 1996.
7. Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. [erratum appears in Pharmacol Rev 59(1): 124, 2007.] Pharmacol Rev 58(3): 621-681, 2006.
8. Daud A, Munster P and Spriggs DR: New drugs in gynecologic cancer. Curr Treat Options Oncol 2(2): 119-28, 2001.
9. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y and Yaegashi N: Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16(1): 52-56, 2006.
10. Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: Considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52: S103-S127, 2008.
11. Zhang M, Lee AH, Binns CW and Xie X: Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer 112: 465-469, 2004. (Pubitemid 39390612)
12. Lev-Ari S, Zinger H, Kazanov D, Yona D, Ben-Yosef R, Starr A, Figer A and Arber N: Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother 59(Suppl 2): S276-S280, 2005.
13. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar APN and Dou QP: Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 68(18): 7283-7292, 2008.
14. Beevers CS, LiF, Liu L and Huang S: Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer 119(4): 757-764, 2006. (Pubitemid 44051438)
15. Chen H-W, Lee J-Y, Huang J-Y, Wang C-C, Chen, W-J, Su S-F, Huang C-W, Ho C-C, Chen JJW, Tsai M-F, Yu S-L and Yang P-C: Curcumin inhibits lung cancer cell. Invasion and Metastasis through the Tumor Suppressor HLJ1. Cancer Res 68(18): 7428-7438, 2008.
16. Shi M, Cai Q, Yao L, Mao Y, Ming Y and Ouyang G: Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int 30(3): 221-226, 2006. (Pubitemid 43276447)
17. Zheng LD, Tong QS and Wu CH: Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780. Chin J Integr Med 12(2): 126-131, 2006.
18. 2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 6(2): 178-184, 2007. (Pubitemid 46641620)
19. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB and Aggarwal BB: Curcumin and cancer: an old age disease with an age-old solution. Cancer Lett 267: 133-164, 2008.
20. Aggarwal BB, Sundaram C, Malani N and Ichikawa H: Curcumin: the Indian solid gold. Ad Exp Med Biol 595: 1-75, 2007.
21. Yang CS and Wang Z-Y: Tea and Cancer. J Nat Cancer Inst 85(13): 1038-1049, 1993. (Pubitemid 23199184)
22. Feng WY: Metabolism of green tea catechins: an overview. Curr Drug Metab 7: 755-809, 2006.
23. Borek C: Dietary antioxidants and human cancer. Integr Cancer Therap 3(4): 333-341, 2004.
24. Huh SW, Bae SM, Kim,Y-W, Lee JM, Namkoong SE, Lee IP, Kim SH, Kim CK and Ahn WS: Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines. Gynecol Oncol 94(3): 760-768, 2004. (Pubitemid 39194472)
25. Chan MM, Soprano KJ, Weinstein K and Fong D: Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207(2): 389-396, 2006.
26. Azam S, Hadi N, Khan NU and Hadi SM: Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties. Toxicol In Vitro 18(5): 555-561, 2004. (Pubitemid 38900862)
27. 2]. Indian J Chem 8: 193-194, 1970.
28. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63, 1983.
29. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
30. Di Blasi P, Bernareggi A, Beggiolin G, Piazzoni L, Menta E and Formento ML: Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin-resistant murine leukemia cells. Anticancer Res 18(4C): 3113-3117, 1998. (Pubitemid 28388825)
31. Bowtell DD: Rapid isolation of eukaryotic DNA. Anal Biochem 162(2 SU): 463-465, 1987.
32. Roberts JD, Van Houten B, Qu Y and Farrell NP: Interaction of novel bis(platinum) complexes with DNA. Nucleic Acids Res 17(23): 9719-9733, 1989. (Pubitemid 20010779)
33. Montopoli M, Ragazzi E, Froldi G and Caparrotta L: Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif 42: 195-206, 2009.
34. Eastman A and Shuttle N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27(13): 4730-473, 1988.
35. Kelland LR: Preclinical perspectives on platinum resistance. Drugs 59(Suppl 4): 1-8; discussion 37-38, 2000.
36. Masuda M, Suzui M and Weinstein IB: Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinomas cell lines. Clin Cancer Res 7: 4220-7429, 2001.
37. Siomek A, Tujakowski J, Gackowski D, Rozalski R, Foksinski M, Dziaman T, Roszkowski K and Olinski R: Severe oxidatively damaged DNA after cisplatin treatment of cancer patients. Int J Cancer 119(9): 2228-2230, 2006. (Pubitemid 44423686)
38. Fang J, Lu J and Holmgren A: Thioredoxin reductase is irreversibly modified by curcumin: A novel molecular mechanism for its anticancer activity. J Biol Chem 280: 25284-25290, 2005. (Pubitemid 40934623)
39. Jandial DD, Farshi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ and Howell SB: Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15n: 553-560, 2009.
40. Umeda D, Yano S, Yamada K and Tachibana H: Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J Biol Chem 283(6): 3050-3058, 2008.
41. Sandur SK, Ichikawa H, Pandey MK, Kunnumakkara AB, Sung B, Sethi G and Aggarwal BB: Role of prooxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferoloylmethane). Free Radic Biol Med 43: 568-580, 2007. (Pubitemid 47058232)
42. Huq F, Yunos NH, Beale P, Yu JQ and Strain D: studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines. Anticancer Res 30(1): 4025-4037, 2010.
43. Blaziak J, Trzeciak A and Kowalik J: Curcumin damages DNA in human gastricmucosa cells and lymphocytes. J Environ Pathol Toxicol Oncol 18: 271-276, 1999. (Pubitemid 30140319)